Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(4.71)
# 758
Out of 4,707 analysts
483
Total ratings
49.1%
Success rate
13.4%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Reiterated: Buy | $36 | $27.58 | +30.53% | 55 | Sep 3, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $64 | $38.23 | +67.41% | 20 | Sep 2, 2026 | |
| BHVN Biohaven | Reiterated: Buy | $21 | $14.72 | +42.66% | 6 | Aug 28, 2026 | |
| ANVS Annovis Bio | Reiterated: Buy | $17 | $1.30 | +1,207.69% | 12 | Aug 18, 2026 | |
| HELP Cybin | Reiterated: Buy | $42 | $12.39 | +238.98% | 26 | Aug 17, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $20 | $14.04 | +42.45% | 26 | Aug 13, 2026 | |
| CRVO CervoMed | Reiterated: Buy | $27 → $18 | $2.53 | +611.46% | 21 | Aug 12, 2026 | |
| VYGR Voyager Therapeutics | Reiterated: Buy | $12 | $3.40 | +252.94% | 41 | Aug 12, 2026 | |
| STOK Stoke Therapeutics | Reiterated: Buy | $58 | $30.06 | +92.95% | 18 | Aug 12, 2026 | |
| ZVRA Zevra Therapeutics | Reiterated: Buy | $20 | $12.68 | +57.79% | 20 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 | $27.79 | +40.34% | 18 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 → $210 | $155.13 | +35.37% | 42 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $245 → $248 | $212.50 | +16.71% | 84 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $24 | $13.95 | +72.04% | 3 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $8 | $7.28 | +9.89% | 23 | Jul 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $3.62 | +1,281.22% | 12 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $120 → $36 | $1.94 | n/a | 10 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $75 → $12 | $29.50 | n/a | 12 | Jan 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $32.79 | n/a | 4 | Apr 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $36.76 | n/a | 9 | Jan 31, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $66 → $53 | $16.61 | n/a | 8 | Nov 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $35 → $19 | $17.05 | n/a | 4 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $109 | $14.58 | n/a | 2 | Jun 14, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $193.20 | $8.86 | n/a | 7 | Dec 18, 2015 |
ACADIA Pharmaceuticals
Sep 3, 2026
Reiterated: Buy
Price Target: $36
Current: $27.58
Upside: +30.53%
Definium Therapeutics
Sep 2, 2026
Reiterated: Buy
Price Target: $64
Current: $38.23
Upside: +67.41%
Biohaven
Aug 28, 2026
Reiterated: Buy
Price Target: $21
Current: $14.72
Upside: +42.66%
Annovis Bio
Aug 18, 2026
Reiterated: Buy
Price Target: $17
Current: $1.30
Upside: +1,207.69%
Cybin
Aug 17, 2026
Reiterated: Buy
Price Target: $42
Current: $12.39
Upside: +238.98%
COMPASS Pathways
Aug 13, 2026
Reiterated: Buy
Price Target: $20
Current: $14.04
Upside: +42.45%
CervoMed
Aug 12, 2026
Reiterated: Buy
Price Target: $27 → $18
Current: $2.53
Upside: +611.46%
Voyager Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $12
Current: $3.40
Upside: +252.94%
Stoke Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $58
Current: $30.06
Upside: +92.95%
Zevra Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $20
Current: $12.68
Upside: +57.79%
Aug 6, 2026
Maintained: Buy
Price Target: $39
Current: $27.79
Upside: +40.34%
Aug 3, 2026
Reiterated: Buy
Price Target: $200 → $210
Current: $155.13
Upside: +35.37%
Jul 30, 2026
Reiterated: Buy
Price Target: $245 → $248
Current: $212.50
Upside: +16.71%
Jul 27, 2026
Maintained: Buy
Price Target: $35 → $24
Current: $13.95
Upside: +72.04%
Jul 17, 2026
Reiterated: Buy
Price Target: $17 → $8
Current: $7.28
Upside: +9.89%
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $3.62
Upside: +1,281.22%
Jun 12, 2024
Downgraded: Hold
Price Target: $120 → $36
Current: $1.94
Upside: n/a
Jan 28, 2022
Downgraded: Hold
Price Target: $75 → $12
Current: $29.50
Upside: n/a
Apr 9, 2018
Maintained: Hold
Price Target: n/a
Current: $32.79
Upside: n/a
Jan 31, 2017
Upgraded: Buy
Price Target: n/a
Current: $36.76
Upside: n/a
Nov 9, 2016
Reiterated: Buy
Price Target: $66 → $53
Current: $16.61
Upside: n/a
Nov 7, 2016
Reiterated: Sell
Price Target: $35 → $19
Current: $17.05
Upside: n/a
Jun 14, 2016
Reiterated: Sell
Price Target: $109
Current: $14.58
Upside: n/a
Dec 18, 2015
Maintained: Buy
Price Target: $193.20
Current: $8.86
Upside: n/a